Lipidor AB (publ) announced that the company has filed a new patent application with the European Patent Office (EPO). The patent originates from the development that took place during the reformulation work with AKP02, now AKP02G2. In line with Lipidor's strategy, the company continuously reviews and works to further strengthen and expand patent protection for its AKVANO-technology. The new patent application is based on the development work carried out over the past year, which led to an updated formulation of the company's most important drug candidate for the treatment of psoriasis, AKP02G2. The new patent application (a so-called priority application) was filed with the European Patent Office (EPO) on October 27, 2023, and also covers the use of the formulation technology in other treatment areas. With the new patent application, AKP02G2 and a number of other applications of the
technology (subject to approval by the patent authorities) will be patent protected until 2044.